Compare · FRNM vs GH
FRNM vs GH
Side-by-side comparison of Freenome Inc. (FRNM) and Guardant Health Inc. (GH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FRNM and GH operate in Medical Specialities (Health Care), so they compete in similar markets.
- GH is the larger of the two at $20.52B, about 17.7x FRNM ($1.16B).
- GH has been more active in the news (21 items in the past 4 weeks vs 3 for FRNM).
- GH has more recent analyst coverage (25 ratings vs 0 for FRNM).
- Company
- Freenome Inc.
- Guardant Health Inc.
- Price
- -
- -
- Market cap
- $1.16B
- $20.52B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 3
- 21
- Recent ratings
- 0
- 25
Freenome Inc.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's development of SimpleScreen CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals.
Guardant Health Inc.
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic individuals eligible for cancer screening; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for residual disease and recurrence monitoring; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. Daiichi Sankyo has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Latest FRNM
Latest GH
- Director Azar Alex M Ii converted options into 138 shares, increasing direct ownership by 15% to 1,031 units (SEC Form 4)
- Director Sayer Kevin R was granted 3,149 restricted stock units (SEC Form 4)
- Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New insider Sayer Kevin R claimed no ownership of stock in the company (SEC Form 3)
- Chief Accounting Officer Parks Robert was granted 18,893 restricted stock units (SEC Form 4)
- New insider Parks Robert claimed no ownership of stock in the company (SEC Form 3)
- Guardant Health Prices $500 Million Convertible Senior Notes Offering
- Guardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032
- Guardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® Liquid
- PRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer Metastases